PND6 ESTIMATION OF PER-MEMBER-PER-YEAR COSTS FOR MANAGING FALLS OR FRACTURES AMONG HYPNOTIC USERS IN A MANAGED CARE PLAN

Greater Pulp Yields per Acre per Year

An examination of periodontal treatment and per member per month (PMPM) medical costs in an insured population

BACKGROUND Chronic medical conditions have been associated with periodontal disease. This study examined if periodontal treatment can contribute to changes in overall risk and medical expenditures for three chronic conditions [Diabetes Mellitus (DM), Coronary Artery Disease (CAD), and Cerebrovascular Disease (CVD)]. METHODS 116,306 enrollees participating in a preferred provider organization ...

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

BACKGROUND Several anti-inflammatory biologic medications are available in the United States for the treatment of moderate-to-severe rheumatoid arthritis, moderate-to-severe psoriasis, psoriatic arthritis, or ankylosing spondylitis. The tumor necrosis factor (TNF) blockers etanercept, adalimumab, and infliximab are approved for use in adults with any of these conditions, but predicting the annu...

Influenza vaccination, hospitalizations, and costs among members of a Medicare managed care plan.

OBJECTIVE To evaluate the effectiveness and possible cost savings of influenza vaccination. SUBJECTS Members age 65 and older in a Medicare managed care plan during the 1994-1995, 1995-1996, and 1996-1997 influenza seasons. RESEARCH DESIGN The study examined administrative data on influenza vaccination and subsequent hospitalizations. Outcomes included hospitalization with pneumonia or infl...

All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.

BACKGROUND Approximately 3.2-3.9 million U.S. residents are infected with the hepatitis C virus (HCV). Total annual costs (direct and indirect) in the United States for HCV were estimated to be $5.46 billion in 1997, and direct medical costs have been predicted to increase to $10.7 billion for the 10-year period from 2010 through 2019, due in part to the increasing number of HCV patients develo...